While agreeing with the proposition that Kevin Trudeau is nothing but a thief and a repeatedly-convicted con artist, you are advised to do ten minutes of research. For starters, 300 to 500 Americans drop deader than a doornail each year from taking a "normal" dosage of
aspirin. That's just for starters.
Over 10 percent of patients who take low-dose aspirin to ward off a heart attack develop peptic ulcers, which often have no symptoms.
This was the finding of researchers at the University of Western Sydney in Australia. Tthey studied 187 patients (with endoscopy) who had been taking 75 milligrams to 325 milligrams of aspirin daily for at least a month.
The researchers found that 10.7 percent of patients in their study developed ulcers at least 3 millimeters in diameter. However, only 20 percent experienced symptoms that were significantly different from patients with no ulcers, which means many people may not know the ulcers exist.
After three months, endoscopy was repeated among the 113 people who did NOT have ulcers when the study began. Over 7 percent had developed an ulcer during this period. This boosted the annual ulcer rate to 28 percent.
All the large long term trials of aspirin after myocardial infarction show no effect on mortality
Aspirin may change the way vascular events present rather than prevent them
This may lead to a "cosmetic" reduction in non-fatal events and an increase in sudden death
Data on the safety and cost-benefit of aspirin are inadequate
Advocating the use of aspirin for preventing atherosclerotic events diverts attention from other, more effective, drugs
Trials Do Not Show That Aspirin Saves Lives
Meta-analysis is increasingly viewed either as a way of verifying that the outcome of an individual trial is consistent with the rest of the known data or as a way of generating a hypothesis.
However, in the absence of a definitively positive trial, many consider meta-analysis inadequate evidence for clinical decision making. The series of meta-analyses from the trialists' collaboration contains serious additional flaws.
It is remarkable and probably statistically significant how seldom trials of antiplatelet agents have shown benefit on their selected primary outcome. The choice of the primary endpoint by the Antithrombotic Trialists' Collaboration is arbitrary and suspect.
Antiplatelet agents seem to be substantially more effective in reducing the incidence of non-fatal events than in reducing death. Indeed, among large long-term trials after myocardial infarction there is no evidence that aspirin saves lives.
In short, any doctor who suggests aspirin is not much of a doctor. More importantly, you, I, and the rest of the human all have a common trait:
WE ARE FOOLISH TO LISTEN TO ANY ONE PERSON OR SOURCE. Get your fingers busy and obtain a dozen or more "expert" opinions before forming your own. Be well!
NatDoc